Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB 56 Price-to-Operating-Cash-Flow is 26.36 as of Aug. 20, 2026, which is 469% above its 10-year median of 4.63. GuruFocus rates XMAD:LAB with a GF Score™ of 56/100 and a GF Value™ of €3.62 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 699 Drug Manufacturers companies, Labiana Health ranks worse than 67.38% on this metric.
As of today (2026-08-20), Labiana Health's share price is €6.30.
Labiana Health's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.24. Hence, Labiana Health's Price-to-Operating-Cash-Flow Ratio for today is 26.36.
The historical rank and industry rank for Labiana Health's Price-to-Operating-Cash-Flow or its related term are showing as below:
XMAD:LAB'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.68 Med: 4.63 Max: 31.65
Current: 26.36
During the past 6 years, Labiana Health's highest Price-to-Operating-Cash-Flow Ratio was 31.65. The lowest was 1.68. And the median was 4.63.
XMAD:LAB's Price-to-Operating-Cash-Flow is ranked worse than 67.38% of 699
companies
in the Drug Manufacturers industry
Industry Median: 16.78
vs XMAD:LAB: 26.36
Labiana Health's Cash Flow from Operations per share for the
six
months ended in Dec. 2025 was €0.31.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.24.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Labiana Health was -75.70% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -28.00% per year.
During the past 6 years, Labiana Health's highest 3-Year average Operating Cash Flow per Share Growth Rate was 22.50% per year. The lowest was -28.00% per year. And the median was -2.75% per year.
Labiana Health Price-to-Operating-Cash-Flow Related Terms
Labiana Health Price-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Labiana Health's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: Price-to-Operating-Cash-Flow Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Labiana Health's Price-to-Operating-Cash-Flow falls into.
Labiana Health Price-to-Operating-Cash-Flow Calculation
Labiana Health's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio
=
Share Price
/
Cash Flow from Operations per share (TTM)
=
6.30
/
0.239
=
26.36
Labiana Health's Share Price of today is €6.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labiana Health's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.24.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Operating-Cash-Flow of 26.36 mean?
Labiana Health (XMAD:LAB) has a Price-to-Operating-Cash-Flow of 26.36 as of Aug. 20, 2026. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Labiana Health and its competitors. This is 469% above median its historical median of 4.63. Over the past decade, Labiana Health's Price-to-Operating-Cash-Flow has ranged from 1.68 to 31.65. According to the industry distribution chart, Labiana Health ranks #471 out of 699 companies in the Drug Manufacturers industry, placing it in the top 67.4%.
Is Labiana Health's Price-to-Operating-Cash-Flow too high?
Labiana Health's current Price-to-Operating-Cash-Flow of 26.36 is 469% above median its 10-year median of 4.63. Over the past 10 years, this metric has ranged from a low of 1.68 to a high of 31.65. The Drug Manufacturers industry median Price-to-Operating-Cash-Flow is 16.78. Labiana Health's value of 26.36 is 57.1% above this industry median. Based on the distribution chart, Labiana Health ranks #471 out of 699 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Labiana Health has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Price-to-Operating-Cash-Flow compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #471 out of 699 companies for Price-to-Operating-Cash-Flow. This places Labiana Health in the lower half of its industry. The industry median Price-to-Operating-Cash-Flow is 16.78. Labiana Health's value of 26.36 is 57.1% above this benchmark. Historically, Labiana Health's own Price-to-Operating-Cash-Flow has ranged from 1.68 to 31.65 over the past decade. While the company's 10-year median is 4.63 vs. the industry median of 16.78, Labiana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Operating-Cash-Flow for a Drug Manufacturers company?
The median Price-to-Operating-Cash-Flow among Drug Manufacturers companies is 16.78, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Price-to-Operating-Cash-Flow of 26.36 is 57.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Operating-Cash-Flow mean?
A high Price-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Price-to-Operating-Cash-Flow is 16.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Price-to-Operating-Cash-Flow is 26.36, which is 469% above median its own 10-year median of 4.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.62, compared to a current price of €6.30 — trading 74% above its estimated fair value. The current Price-to-Operating-Cash-Flow is 26.36, which is 469% above median its 10-year median of 4.63 and 57.1% above the Drug Manufacturers industry median of 16.78. Labiana Health's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Operating-Cash-Flow calculated?
Price-to-Operating-Cash-Flow is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Price-to-Operating-Cash-Flow is 26.36 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.30 is trading 74% above its estimated GF Value™ of €3.62.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Price-to-Operating-Cash-Flow: 26.36 (469% above median its 10-year median of 4.63)
GF Value™: €3.62 vs. price of €6.30 (74% above fair value)
Industry Position: 57.1% above the Drug Manufacturers median (#471 of 699)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
56GF Score
Get the complete analysis for XMAD:LAB
Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
